

Original article

Hyperbaric index in the primary prevention of hypertensive complications in high-risk pregnancy[☆]

Alfonso Otero González^{a,*}, Silvia Uribe Moya^a, Ivan Gilberto Arenas Moncaleano^a,
María Paz Borrajo Prol^a, María Jesús García García^a, Luis López Sánchez^b

^a Servicio de Nefrología, Centro Hospitalario Universitario de Ourense, Ourense, Spain

^b Documentación Clínica, Centro Hospitalario Universitario de Ourense, Ourense, Spain

ARTICLE INFO

Article history:

Received 23 December 2014

Accepted 15 April 2015

Available online 25 January 2016

Keywords:

Pregnancy

Hyperbaric index

Hypertension

ABSTRACT

Introduction: Preeclampsia (PE) is a major cause of fetal morbidity and mortality. In the Western World, PE affects 2–7% of pregnancies and is responsible for 50,000 deaths annually. Early detection is a priority as it can change the clinical course, but there are no biomarkers or instrumental methods with high sensitivity and specificity. Only the hyperbaric index has a sensitivity and specificity of 99% for early identification of pregnant women at risk of developing PE, but its use is not widespread.

Objective: To assess the usefulness of the hyperbaric index in the primary prevention of hypertensive pregnancy complications in a public healthcare area.

Material and methods: This is a retrospective study of pregnancies that occurred in our area during the period 2007–2012 (N = 11,784). The diagnosis was established by the hyperbaric index and pregnant women at risk were treated with ASA at night.

Results: In pregnant patients referred to the nephrology clinic (38.2%), diagnosed as high-risk for PE, and treated with 100 mg ASA/night (from week 17), the incidence of PE episodes was reduced by 96.94%.

© 2015 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Índice hiperbárico en la prevención primaria de las complicaciones hipertensivas del embarazo de alto riesgo

RESUMEN

Introducción La preeclampsia (PE) es una importante causa de morbimortalidad fetal, que en el mundo occidental afecta al 2–7% de los embarazos y es responsable de 50.000 muertes

Palabras clave:

Embarazo

Índice hiperbárico

Hipertensión

[☆] Please cite this article as: González AO, Moya SU, Arenas Moncaleano IG, Borrajo Prol MP, García García MJ, López Sánchez L. Índice hiperbárico en la prevención primaria de las complicaciones hipertensivas del embarazo de alto riesgo. Nefrología. 2015;35:572–577.

* Corresponding author.

E-mail address: alfonso.otero.gonzalez@sergas.es (A.O. González).

2013-2514/© 2015 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

anuales. La detección precoz es prioritaria, ya que puede cambiar su curso clínico, pero no se dispone de biomarcadores ni métodos instrumentales de alta sensibilidad y especificidad, solamente el índice hiperbárico tiene una sensibilidad y una especificidad del 99% para la identificación precoz de las gestantes en riesgo de desarrollo de PE, pero está escasamente difundido.

Objetivo: Valorar la utilidad del índice hiperbárico en la prevención primaria de las complicaciones hipertensivas del embarazo en un área sanitaria.

Material y métodos: Estudio retrospectivo realizado entre los embarazos habidos en nuestra área durante el periodo 2007-2012 (N = 11.784). El diagnóstico se estableció mediante el índice hiperbárico y las gestantes en riesgo fueron tratadas con AAS nocturno.

Resultados: En las gestantes remitidas a consulta de Nefrología (38,2%), diagnosticadas de alto riesgo de PE y tratadas con AAS 100 mg nocturno (desde la semana 17) se redujo la incidencia de episodios de PE un 96,94%.

© 2015 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

High blood pressure (HTN) is the most common clinical complication during pregnancy, and preeclampsia (PE) is a major cause of fetal morbi-mortality (low-birth weight or premature birth), and maternal complications including acute renal failure, HELLP syndrome, liver failure and even brain edema, seizures and death.¹ In the Western world, PE affects a 2-7% of all pregnancies, and the basic pathogenic phenomenon is endothelial dysfunction caused by an imbalance of angiogenic factors producing placental abnormalities with ischemia. Endothelial dysfunction is not a limited process that is resolved at birth, but may persist and pose a future cardiovascular risk.²

Therefore, even though PE should be diagnosed early, angiogenic factors are not sensitive or specific enough to be used in clinical practice^{3,4}; neither is hyperuricemia, although it is often correlated with the degree of severity early initiation of PE; according to two recent systematic reviews, evidence supporting a correlation between hyperuricemia and PE is limited.⁵ In addition, these reviews have shown that uric acid is a poor predictor of maternal-fetal complications.⁶ In our experience, based on the use of the hyperbaric index (HBI) as the gold standard, risk factors including primiparous pregnancies in advance age, use of oral contraceptive drugs, or a family history of HTN are predictive of PE.⁷

For instrumental methods, experts do not recommend the use of the uterine artery Doppler⁸; however, the HBI or the area of blood pressure (BP) excess above the upper limit of the tolerance range has a 99% sensitivity and specificity for the early screening of pregnant patients at risk of PE⁹; only the identification of preeclampsia by the proteomic profiling of urine¹⁰ or the evidence of podocyturia have a 100% sensitivity and specificity.¹¹ Once the risk is detected, PE is significantly reduced by the early administration of ASA¹² and vitamin D¹³ at night.

Therefore, the diagnosis is made with an HBI greater than 12, in addition to conventional risk factors, and prevention includes a high-dose of ASA, 100-300 mg at night, resulting in a significantly reduced risk of hypertensive complications resulting from pregnancy before week 17.

The objective of the present work is to assess the use of the HBI for the primary prevention of PE in our health sector.

Materials and methods

This was a retrospective study in pregnant women followed in our area between 2007 and 2012 (N = 11,784). We reviewed the incidence of PE in pregnant women with high risk (HR) consultations and consultations "without HR" from three local hospitals (University Hospital Complex of Ourense [Complejo Hospitalario Universitario de Ourense, CHUOU]), the regional hospital ([Hospital Comarcal, HC] of Verín and Valdeorras) and in HR pregnant women referred to Nephrology Consultation (NC) services. In pregnant women referred to NC (before the 17th week of pregnancy), BP was monitored for 48 hs as an outpatients using Spacelab 92007. An HBI of greater than 12 was considered a marker of PE risk (Fig. 1), and pregnant women with a pathologic HBI were treated with 100 mg of AAS and vitamin D supplements at night provided that they had vitamin D deficiency. These pregnant women were monitored throughout pregnancy in the nephrology outpatient clinics.

HR pregnant women were defined as women who met any of the following criteria: elderly pregnant woman, morbid obesity, previous history of PE, diabetes mellitus, HTN, systemic disease (DLE, antiphospholipid syndrome), cardiopathy, family history of cardiovascular disease, smoking, twin pregnancy, or use of oral contraceptives.

Results

The total number of deliveries between 2005 and 2012 was 11,784 (Fig. 2), of which 85.20% took place in the CHUOU, 7.82% in the HC of Valdeorras, and 6.91% in the HC of Verín, and the mean age of these pregnant women attended in these different centers ranged from 30 to 31.63 years old (Fig. 2). Referral from Obstetrics to HR clinics in regional centers was exceptional: 0.4% in the HC of Valdeorras and 1.70% in the HC of Verín, whereas in the CHUOU, the percent of referrals was of 14.28%. Only 34.93% of these pregnant women were referred




Fig. 1 - (A) Normal ABPM. Excess area (red circle) less than 12. (B) Pathological ABPM. Excess area (red circle) greater than 12; the arrow points to the “excess area”: HBI is above a normal blood pressure threshold for pregnant woman.




Fig. 2 – Total number of deliveries between 2005 and 2012.

to NC, 61.8% of them had a HBI greater than 12, while 32.8% of them showed a normal HBI.

The incidence of PE was 4 episodes/year in the HC of Valdeorras and 2.3 episodes/year in the HC of Verín. In the CHUOU, the incidence of PE among pregnant women who were not referred to NC was 20 episodes/year, whereas 0.8 episodes/year were reported among patients attending NCs including four pregnant women, two of whom had DLE, the third had intolerance to ASA, and the fourth had HELLP syndrome.

Discussion

PE is a syndrome characterized by HTN and proteinuria after the 20th week of pregnancy in women with no previous history of HTN or proteinuria. In the Western world it affects between 2% and 7% of all pregnancies, although it may be threefold greater in other geographical regions.¹⁴ Mortality is 10–15%, with nearly 50,000 deaths every year. Therefore, early detection is crucial and may alter its clinical course.

The basic mechanism is a defect in placental implantation. In a normal pregnancy the cytotrophoblast overregulates metalloproteinase expression causing the conversion of epithelium to endothelium, a process mediated by the vascular endothelium growth factor (VEGF), the placental growth factor (PlGF), and angiotensin.

In PE, there is an increase in placental and serum levels of the antiangiogenic circulating factor, sFlt-1, which binds to PlGF and VEGF and inhibits the interaction with its endothelial receptors (Flt1); as a result, NOse is also activated, resulting in oxidative stress and placental ischemia. In PE, these factors are elevated levels at weeks 9 and 11, together with a concurrent decrease in PlGF before the onset of PE.¹⁵

In addition to angiotensin,¹⁶ other factors involved in the development of PE are low oxygen rates, resistance to insulin,¹⁷ and vitamin D deficiency. VEGF is regulated by vitamin D,¹⁸ and vitamin D deficiency-insufficiency in PE women leads to endothelial dysfunction and HTN. Finally, among other problems, placental abnormalities in the mother give rise to increased peripheral resistances due to the activity of AT1 agonistic antibodies¹⁹ and increased endoglin levels, a co-receptor of TGF B1 and TGF B3, which acts as a potent anti-angiogenic protein, “kidnapping” PlGF and VEGF.

Paradoxically, none of these factors have the sensitivity-specificity and availability required for clinical use³ in the early diagnosis of PE, neither are conventional vascular risk factors^{5,6} or instrumental methods,⁸ except for BP. In early pregnancy, BP was classically considered to be useful for PE screening, and although accuracy was higher when mean BP was above 90 mmHg, its predictive value was low.²⁰ These poor outcomes of the static measurement of BP resulted from the use of the threshold for the definition of essential HTN. The pattern of BP in women with PE or HTN is known to be different and predictable; this way, differences in BP between a

normotensive pregnant woman and a pregnant woman with complications (PE or gestational HTN) are detected from the first trimester with significant differences in the circadian MESOR of systolic (12 mmHg) and diastolic (7 mmHg) BP. As a result, the “quantification” of the “excess” in the threshold of BP or HBI, with a 99% sensitivity-specificity, allows for the screening of pregnant women at risk of PE.⁹

In our series, HBI was pathological in 61.9% of pregnant women referred from HR visits, but it was normal in 38.2%, thereby showing that HBI allows for a more accurate differentiation than conventional AR criteria.⁹ Pregnant women at high risk of PE were identified “early”, and treatment decreased its incidence from 26.3 to 0.8 episodes/year, mainly in the CHUOU, which accounts for the 34% of HR pregnant women we received. No HR pregnant women came from the 2 HC, and the rate of PE remained similar to that of areas where primary care is not available.¹⁴ Protocols are common and this situation may have resulted from “clinical inertia”.

Activated platelets and coagulation system, leading to an imbalance between the synthesis of prostacyclins and thromboxane A₂, result from the ischemic placental damage in PE. Therefore, several studies to assess the use of antiaggregants in the primary prevention of PE were conducted, but the initial results were discouraging,²¹⁻²³ although a review report²⁴ reveals how the risk of PE is reduced by 17% by the use of antiplatelets. All these studies have a methodologic problem: the dose of ASA and the dosing schedule. Several studies have shown that 100–150 mg/dl of ASA is effective compared to lower dosing (50–80 mg/dl)²⁵ and that it should be administered before week 17 and at night,¹² considering that inhibition of the thromboxane A₂ synthesis by ASA is dose-dependent and that the dose is administered at night. Consequently, all pregnant women referred to NC (34.92%) and with a HBI greater than 12 (61.8%) (Fig. 2) were treated with 100 mg of ASA at night during the entire pregnancy, and the incidence of PE episodes was decreased 96.94%.

In conclusion, the use of NC for the primary prevention of HTN complications during pregnancy and the use of the HBI as a diagnostic method is highly effective, and this is why routine healthcare exams should be conducted between HR consultations and Nephrology consultations during pregnancy.

Conflicts of interest

The authors have no conflicts of interest to declare.

REFERENCES

1. Roberts JM, Pearson G, Cutler J, Lindheimer M, NHLBI Working Group on Research on Hypertension During Pregnancy. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. *Hypertension*. 2003;41:437–45.
2. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ*. 2007;335:974.
3. Kuc S, Wortelboer EJ, van Rijn BB, Franx A, Visser GH, Schielen PC. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. *Obstet Gynecol Surv*. 2011;66:225–39.
4. Akolekar R, de Cruz J, Foidart JM, Munaut C, Nicolaides KH. Maternal plasma soluble FMS-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. *Prenat Diagn*. 2010;30:191–7.
5. Cnossen JS, de Ruyter-Hanhijarvi H, van der Post JA, Mol BW, Khan KS, ter Riet G. Accuracy of serum uric acid determination in predicting pre-eclampsia: a systematic review. *Acta Obstet Gynecol Scand*. 2006;85:519–25.
6. Thangaratinam S, Ismail KM, Sharp S, Coomarasamy A, Khan KS. Tests in Prediction of Pre-eclampsia Severity review group. Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. *BJOG*. 2006;113:369–78.
7. Borrajo M, Santos Norez J, Novoa Fernandez E, Blanco Garcia M, Conde Rivera O, Blanco S, et al. Factores de riesgo como predictores de preeclampsia/eclampsia en embarazadas con índice hiperbárico patológico. XXXVIII Congreso Nacional de la SEN Donostia Octubre 2008. *Nefrologia*. 2008;28:17.
8. Papageorghiou AT, Yu CK, Nicolaides KH. The role of uterine artery Doppler in predicting adverse pregnancy outcome. *Best Pract Res Clin Obstet Gynaecol*. 2004;18:38312.
9. Hermida RC, Ayala DE, Mojón A, Fernández JR, Silva I, Ucieda R, et al. Blood pressure excess for the early identification of gestational hypertension and preeclampsia. *Hypertension*. 1998;31:83–8.
10. Buhimschi IA, Zhao G, Funai EF, Harris N, Sasson IE, Bernstein IM, et al. Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia. *Am J Obstet Gynecol*. 2008;199:551.e1–16.
11. Craici IM, Wagner SJ, Bailey KR, Fitz-Gibbon PD, Wood-Wentz CM, Turner ST, et al. Podocyturia predates proteinuria and clinical features of preeclampsia: longitudinal prospective study. *Hypertension*. 2013;61.
12. Hermida RC, Ayala DE, Iglesias M, Mojón A, Silva I, Ucieda R, et al. Time-dependent effects of low-dose aspirin administration on blood pressure in pregnant women. *Hypertension*. 1997;30:589–95.
13. Bodnar LM, Catov JM, Simhan HN, Holick MF, Powers RW, Roberts JM. Maternal vitamin D deficiency increases the risk of preeclampsia. *J Clin Endocrinol Metab*. 2007;92:3517–22.
14. Villar J, Say L, Gulmezoglu AM, Meraldi M, Lindheimer MD, Betran AP, et al. Eclampsia and pre-eclampsia a health problem for 2000 years. In: Critchley H, MacLean A, Poston L, Walker J, editors. *Pre-eclampsia*. London: RCOG Press; 2003. p. 189–207.
15. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. *N Engl J Med*. 2004;350:672–83.
16. Burton GJ, Charnock-Jones DS, Jauniaux E. Regulation of vascular growth and function in the human placenta. *Reproduction*. 2009;138:895–902.
17. Elsheikh A, Creatas G, Mastorakos G, Milingos S, Loutradis D, Michalas S. The renin-aldosterone system during normal and hypertensive pregnancy. *Arch Gynecol Obstet*. 2001;264:182–5.
18. Evans KN, Nguyen L, Chan J, Innes BA, Bulmer JN, Kilby MD, et al. Effects of 25-hydroxyvitamin D₃ and 1,25-dihydroxyvitamin D₃ on cytokine production by human decidual cells. *Biol Reprod*. 2006;75:816–22.
19. Xia Y, Zhou CC, Ramin SM, Kellens RE. Angiotensin receptors, autoimmunity, and preeclampsia. *J Immunol*. 2007;179:3391–5.
20. Page EW, Christianson R. The impact of mean arterial pressure in the middle trimester upon the outcome of pregnancy. *Am J Obstet Gynecol*. 1976;125:740–6.
21. Collaborative Low-dose Aspirin Study in Pregnancy Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. *Lancet*. 1994;343:619–29.

-
22. Caritis S, Sibai BM, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. *N Engl J Med.* 1998;338:701-5.
 23. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, on behalf of the PARIS Collaborative Group. Antiplatelets agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. *Lancet.* 2007;369:1791-8.
 24. Knight M, Duley L, Henderson-Smart DJ, King JF. Antiplatelet agents for preventing and treating pre-eclampsia. *Cochrane Database Syst Rev.* 2007;18:CD000492.
 25. Leitich H, Egarter C, Husslein P, Kaidler A, Schemper M. A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation. *Br J Obstet Gynaecol.* 1997;104:450-9.